Exact Sciences (NASDAQ:EXAS - Get Free Report) had its price target cut by Bank of America from $72.00 to $65.00 in a research note issued to investors on Thursday,Benzinga reports. The firm currently has a "buy" rating on the medical research company's stock. Bank of America's price target points to a potential upside of 31.95% from the company's previous close.
EXAS has been the topic of a number of other research reports. Stifel Nicolaus cut their price target on shares of Exact Sciences from $82.00 to $67.00 and set a "buy" rating on the stock in a research note on Wednesday, November 6th. Citigroup lowered their price objective on shares of Exact Sciences from $80.00 to $75.00 and set a "buy" rating on the stock in a report on Wednesday, November 6th. TD Cowen lifted their price objective on shares of Exact Sciences from $82.00 to $86.00 and gave the company a "buy" rating in a report on Tuesday, November 26th. The Goldman Sachs Group lowered their price objective on shares of Exact Sciences from $75.00 to $65.00 and set a "buy" rating on the stock in a report on Wednesday, November 6th. Finally, BTIG Research boosted their target price on shares of Exact Sciences from $65.00 to $75.00 and gave the stock a "buy" rating in a report on Tuesday, November 26th. One investment analyst has rated the stock with a hold rating and eighteen have issued a buy rating to the company. According to MarketBeat, Exact Sciences presently has an average rating of "Moderate Buy" and a consensus price target of $72.06.
Read Our Latest Report on Exact Sciences
Exact Sciences Trading Down 0.5 %
Exact Sciences stock traded down $0.25 during midday trading on Thursday, hitting $49.26. 3,339,540 shares of the stock were exchanged, compared to its average volume of 2,338,169. The company has a fifty day simple moving average of $54.91 and a two-hundred day simple moving average of $59.99. Exact Sciences has a 52 week low of $40.62 and a 52 week high of $79.62. The stock has a market capitalization of $9.12 billion, a PE ratio of -8.84 and a beta of 1.24. The company has a quick ratio of 1.93, a current ratio of 2.12 and a debt-to-equity ratio of 0.72.
Exact Sciences (NASDAQ:EXAS - Get Free Report) last announced its quarterly earnings results on Wednesday, February 19th. The medical research company reported ($0.06) earnings per share for the quarter, beating analysts' consensus estimates of ($0.29) by $0.23. Exact Sciences had a negative net margin of 37.29% and a negative return on equity of 4.97%. The firm had revenue of $713.42 million for the quarter, compared to analyst estimates of $701.45 million. Equities research analysts anticipate that Exact Sciences will post -0.59 EPS for the current fiscal year.
Institutional Trading of Exact Sciences
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Chicago Partners Investment Group LLC increased its stake in shares of Exact Sciences by 1.7% in the 3rd quarter. Chicago Partners Investment Group LLC now owns 9,261 shares of the medical research company's stock valued at $651,000 after acquiring an additional 158 shares in the last quarter. Perigon Wealth Management LLC increased its stake in shares of Exact Sciences by 3.2% in the 4th quarter. Perigon Wealth Management LLC now owns 8,436 shares of the medical research company's stock valued at $474,000 after acquiring an additional 264 shares in the last quarter. Sanctuary Advisors LLC increased its stake in shares of Exact Sciences by 2.0% in the 4th quarter. Sanctuary Advisors LLC now owns 13,625 shares of the medical research company's stock valued at $763,000 after acquiring an additional 269 shares in the last quarter. Daiwa Securities Group Inc. increased its stake in shares of Exact Sciences by 2.1% in the 4th quarter. Daiwa Securities Group Inc. now owns 14,447 shares of the medical research company's stock valued at $812,000 after acquiring an additional 300 shares in the last quarter. Finally, Huntington National Bank increased its stake in shares of Exact Sciences by 838.1% in the 3rd quarter. Huntington National Bank now owns 394 shares of the medical research company's stock valued at $27,000 after acquiring an additional 352 shares in the last quarter. Institutional investors and hedge funds own 88.82% of the company's stock.
Exact Sciences Company Profile
(
Get Free Report)
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.
Recommended Stories
Before you consider Exact Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Exact Sciences wasn't on the list.
While Exact Sciences currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
